Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await

07 Sep 2023

• By Alaric DeArment

Alnylam announced results from the KARDIA-1 trial of zilebesiran • Source: Shutterstock

Related Content

A Look At Leqvio’s Lacklustre Launch

26 Jul 2023

In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill

20 Jul 2023

Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

24 Jul 2023

Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

25 Aug 2023

Buy-And-Bill A Bust For Novartis's Leqvio?

03 Jan 2023

Related Companies

Alnylam Pharmaceuticals Inc.

Roche Holding AG

Novartis AG

Amgen, Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Merck & Co., Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.